Article
Immunology
JianBin Wu, Yuanyuan Zhu, MingMin Luo, Lei Li
Summary: This study revealed the crucial role of pyroptosis in breast cancer, showing its association with tumor progression, prognosis, and immunotherapy response. Evaluating the PyroptosisScore of a single tumor can help understand the characteristics of tumor microenvironment infiltration and lead to the development of more effective immunotherapy strategies.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Iris Tung, Arvind Sahu
Summary: The treatment paradigm for metastatic RCC has shifted dramatically in recent years, with immune checkpoint inhibitors becoming first-line therapy and showing promising results when used in combination with TKIs. Ongoing advances with new targeted agents and biomarkers are needed for further improvements in prognosis.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Da-Liang Ou, Chia-Wei Chen, Chia-Lang Hsu, Chih-Hung Chung, Zi-Rui Feng, Bin-Shyun Lee, Ann-Lii Cheng, Muh-Hwa Yang, Chiun Hsu
Summary: Regorafenib may enhance antitumor immunity by modulating macrophage polarization independently of its anti-angiogenic effects. It enhances the antitumor effects of antigen-specific T cells and shows synergistic effects with anti-PD1 by affecting multiple immune-related pathways in the tumor microenvironment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Meenal Sinha, Courtney Betts, Li Zhang, Madeline J. Griffith, Isabelle Solman, Brandon Chen, Eric Liu, Whitney Tamaki, Jacob Stultz, Jaqueline Marquez, Shamilene Sivagnanam, Alexander Cheung, Denise Pener, Anne Fahlman, Erin Taber, Kimberly Lerner, Matthew Crocker, Kendra Todd, Brindha Rajagopalan, Clarisha Ware, Mark Bridge, Johnson Vo, Hannah Dragomanovich, Julie Sudduth-Klinger, Gina Vaccaro, Charles D. Lopez, Margaret Tempero, Lisa M. Coussens, Lawrence Fong
Summary: In preclinical studies, ibrutinib improved the antitumor efficacy of chemotherapy for PDAC. A phase 1b clinical trial was conducted to determine the safety, tolerability, and immunologic effects of ibrutinib treatment in advanced PDAC patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Cell Biology
Qi Sun, Yujie Wang, Hong Ji, Xiaoting Sun, Sisi Xie, Longtian Chen, Sen Li, Weifan Zeng, Ruibo Chen, Qi Tang, Ji Zuo, Likun Hou, Kayoko Hosaka, Yongtian Lu, Ying Liu, Ying Ye, Yunlong Yang
Summary: Nasopharyngeal carcinoma (NPC) patients have intrinsic resistance to antiangiogenic drugs (AADs), with FGF-2 expression triggering VEGF-independent angiogenesis as a mechanism. Lenvatinib, a multi-kinase inhibitor targeting VEGFR2 and FGFR1, effectively inhibits tumor vasculature and shows strong anti-tumor effects in NPC.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Roberto Moretto, Daniele Rossini, Aurelie Catteau, Carlotta Antoniotti, Mirella Giordano, Alessandra Boccaccino, Clara Ugolini, Agnese Proietti, Veronica Conca, Alboukadel Kassambara, Filippo Pietrantonio, Lisa Salvatore, Sara Lonardi, Stefano Tamberi, Emiliano Tamburini, Anello Marcello Poma, Jacques Fieschi, Gabriella Fontanini, Gianluca Masi, Jerome Galon, Chiara Cremolini
Summary: The expression of tumor-infiltrating lymphocytes (TILs), Immunoscore, Immunoscore-IC, and programmed death ligand-1 (PD-L1) can predict the efficacy of immune-checkpoint inhibitors (ICIs) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Vincenzo Salemme, Giorgia Centonze, Federica Cavallo, Paola Defilippi, Laura Conti
Summary: The progression of breast cancer is influenced by genetic and epigenetic factors that involve interactions between tumor cells and the tumor microenvironment, particularly immune cells. Immune cells in the tumor microenvironment can have dual roles in cancer onset and progression, affecting both tumor suppression and promotion. Understanding the complex interplay between cancer and immune cells, as well as therapeutic strategies targeting this interaction, is crucial for developing effective combination treatments to overcome tumor immune evasion mechanisms and maximize the clinical benefits of current immunotherapies.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Brigida Anna Maiorano, Mauro Francesco Pio Maiorano, Davide Ciardiello, Annamaria Maglione, Michele Orditura, Domenica Lorusso, Evaristo Maiello
Summary: Immune checkpoint inhibitors (ICIs) may be an attractive strategy for the treatment of advanced cervical cancer, with a majority of patients responding to ICIs and PD-L1 status potentially serving as an indicator of response. Further research is needed for appropriate patient selection and personalized treatment.
Review
Chemistry, Medicinal
Ranferi Ocana-Guzman, Diego Osorio-Perez, Leslie Chavez-Galan
Summary: Blocking immune checkpoint receptors is the basis of immunotherapy, but it can also lead to adverse effects such as immunosuppression and infections. This review discusses the immunologic aspects related to these unwanted effects.
Review
Immunology
Yaxiong Tang, Xu Hu, Kan Wu, Xiang Li
Summary: Penile cancer is a rare malignancy with limited treatment options and poor prognosis. Immune-based therapies, HPV vaccine, and adoptive T cell therapy have shown potential as treatment modalities.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Bilal A. Siddiqui, Brian F. Chapin, Sonali Jindal, Fei Duan, Sreyashi Basu, Shalini S. Yadav, Ai-Di Gu, Alexsandra B. Espejo, Michelle Kinder, Curtis A. Pettaway, John F. Ward, Rebecca S. S. Tidwell, Patricia Troncoso, Paul G. Corn, Christopher J. Logothetis, Roland Knoblauch, Natalie Hutnick, Marco Gottardis, Charles G. Drake, Padmanee Sharma, Sumit K. Subudhi
Summary: This study aimed to explore the safety and efficacy of Daratumumab and edicotinib in the treatment of localized prostate cancer. The results showed that these two drugs were safe to use and did not induce complete remission. However, Daratumumab treatment led to a decreased frequency of CD38(+) immune cells in prostate tumors, bone marrow, and peripheral blood mononuclear cells (PBMCs), while edicotinib did not consistently affect CSF-1R(+) immune cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Johanna A. Seier, Julia Reinhardt, Kritika Saraf, Susanna S. Ng, Julian P. Layer, Dillon Corvino, Kristina Althoff, Frank A. Giordano, Alexander Schramm, Matthias Fischer, Michael Hoelzel
Summary: The study identified epigenetic drivers EHMT2 and EHMT1 as effectors of the MYCN-driven malignant phenotype and suppressors of IFN-gamma transcriptional responses in neuroblastoma cells. Inhibitors of EHMT enhanced T-cell recruitment into the tumor microenvironment through increased expression of Th1-type chemokines, which was further potentiated by co-inhibition of EZH2 in MYCN-amplified high-risk neuroblastomas.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Liting Xue, Xingyuan Gao, Haoyu Zhang, Jianxing Tang, Qian Wang, Feng Li, Xinxin Li, Xiaohong Yu, Zhihong Lu, Yue Huang, Renhong Tang, Wenqing Yang
Summary: The study demonstrates that BD0801 has stronger anti-tumor activity by blocking VEGF/VEGFR binding and inhibiting HUVECs. Combining BD0801 with anti-PD-1 or anti-PD-L1 antibodies shows synergistic anti-tumor efficacy in lung and colorectal cancer mouse models. Mechanistic studies suggest that the synergy involves improved tumor vasculature normalization and enhanced T-cell mediated immunity.
Review
Immunology
Muhammad Khan, Kunpeng Du, Meiling Ai, Baiyao Wang, Jie Lin, Anbang Ren, Chengcong Chen, Zhong Huang, Wenze Qiu, Yawei Yuan, Yunhong Tian
Summary: This study systematically analyzed the biomarker value of PD-L1 expression in predicting the efficacy of PD-1/PD-L1 checkpoint inhibitors in mTNBC patients. The results showed that PD-L1+ patients had significantly higher objective response rate, 1-year progression-free survival, and 2-year overall survival compared to PD-L1- patients. Subgroup analysis indicated that PD-L1 expression can successfully predict tumor response and 2-year overall survival benefit in mTNBC patients regardless of the type of investigating agent, line of treatment administration, and to some extent the type of treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell Biology
Mengjia Huang, Lin Liu, Junkai Zhu, Tong Jin, Yi Chen, Li Xu, Wenxuan Cheng, Xinjia Ruan, Liwen Su, Jialin Meng, Xiaofan Lu, Fangrong Yan
Summary: This study identified three distinct ICI subtypes in bladder cancer patients based on the TME immune infiltration pattern, showing that patients with high ICI scores had favorable prognosis and higher expression of immune activity-related genes. The high ICI score subgroup was also associated with increased tumor mutation burden and neoantigen burden, and confirmed therapeutic advantage and clinical benefit in a cohort treated with anti-PD-L1 immunotherapy. The study also demonstrated that the ICI score is an effective prognostic predictor for evaluating the response to immunotherapy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Medicine, Research & Experimental
Lei Sun, Chen Chen, Aijing Zhu, Ying Huang, Hong Zhu, Cheng Yi
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
(2017)
Article
Cell Biology
Ning An, Yaqin Zhao, Haitao Lan, Ming Zhang, Yuan Yin, Cheng Yi
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2020)
Review
Chemistry, Physical
Xi Yang, Ling Gao, Qing Guo, Yongjiang Li, Yue Ma, Ju Yang, Changyang Gong, Cheng Yi
Article
Oncology
Wanting Hou, Mingfu Ding, Xiaohua Li, Xiaohan Zhou, Qing Zhu, Armando Varela-Ramirez, Cheng Yi
Summary: This meta-analysis study investigated the potential cardiotoxicity risks of using VEGFR-TKIs as anticancer drugs. Findings show that lenvatinib had the highest probability of causing cardiovascular incidents and hypertension, followed by vandetanib, cabozantinib, and others. Lenvatinib and vandetanib were ranked to have the most severe cardiotoxicity, while regorafenib and nintedanib did not show an increased risk of cardiac damage.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Yuanfeng Wei, Xi Yang, Limin Gao, Yong Xu, Cheng Yi
Summary: This study compared the differentially expressed genes between primary and secondary breast angiosarcoma and conducted enrichment analysis and protein-protein interaction network analysis. The results identified enrichment in metabolism, energy pathways, and protein metabolism in biological processes, as well as enrichment in signaling pathways such as transforming growth factor-beta, Wnt, Hippo, and PI3K-Akt. The study provides a foundation for the discovery of new biomarkers and therapeutic targets.
TRANSLATIONAL ONCOLOGY
(2022)
Review
Materials Science, Biomaterials
Xi Yang, Yuanfeng Wei, Lingnan Zheng, Jia You, Huawei Li, Ling Gao, Changyang Gong, Cheng Yi
Summary: This review provides an overview of PEI-based adjuvants and discusses strategies for improving and boosting immune response to vaccines, with a particular focus on their application in cancer vaccines. The potential challenges and future issues of PEI-based adjuvants in eliciting the effectiveness of cancer vaccines are also addressed.
JOURNAL OF MATERIALS CHEMISTRY B
(2022)
Review
Materials Science, Biomaterials
Xi Yang, Jia You, Yuanfeng Wei, Huawei Li, Ling Gao, Qing Guo, Ying Huang, Changyang Gong, Cheng Yi
Summary: This review outlines the role of nanomaterials in preventing and treating the cytokine storm of COVID-19, including direct inhibition of cytokine release and delivery of anti-inflammatory drugs. It also highlights the important role of nanomaterials in diagnostics with improved sensitivity and specificity.
JOURNAL OF MATERIALS CHEMISTRY B
(2021)
Article
Computer Science, Information Systems
Yong Luo, Xiaojie Li, Chao Luo, Feng Wang, Xi Wu, Imran Mumtaz, Cheng Yi
CMC-COMPUTERS MATERIALS & CONTINUA
(2020)